Prevalence and burden of bronchiectasis in a lung cancer screening program

Abstract

Introduction The prevalence of bronchiectasis in the general population and in individuals undergoing lung cancer screening with low dose computed tomography (LDCT) is unknown. The aim of this study is to estimate the prevalence and impact of bronchiectasis in a screening lung cancer program. Methods 3028 individuals participating in an international multicenter lung cancer screening consortium (I-ELCAP) were selected from 2000 to 2012. Patients with bronchiectasis on baseline CT were identified and compared to selected controls. Detection of nodules, need for additional studies and incidence of cancer were analyzed over the follow-up period. Results The prevalence of bronchiectasis was 11.6%(354/3028). On the baseline LDCT, the number of subjects with nodules identified was 189(53.4%) in patients with bronchiectasis compared to 63(17.8%) in controls (p<0.001). The occurrence of false positives was higher in subjects with bronchiectasis (26%vs17%;p = 0.003). During follow-up, new nodules were more common among subjects with bronchiectasis (17%vs.12%; p = 0.008). The total number of false positives during follow-up was 29(17.06%) for patients with bronchiectasis vs. 88(12.17%) for controls (p = 0.008).The incidence rate of lung cancer during follow-up was 6.8/1000 and 5.1/1000 person-years for each group respectively (p = 0.62) Conclusions Bronchiectasis are common among current and former smokers undergoing lung cancer screening with LDCT. The presence of bronchiectasis is associated with greater incidence

Mutagenic damage among bronchiectasis patients attending in the pulmonology sector of a hospital in southern Brazil

“…Advanced age appears to be associated with an increase in genomic instability resulting from reduced DNA damage repair capacity 28 . In addition, studies have shown that bronchiectasis seems to be directly related to the emergence of cancers, at a frequency ranging from 0.2–16%, and that age helps to increase these rates among bronchiectasis 23 , 29 .…”

Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report

“…The prevalence of bronchiectasis in participants in lung cancer screening programs has been analyzed in the two different studies of I-ELCAP subcohorts (Cai Q.Y.N., Yip R., Triphuridet N., Yankelevitz D.F., Henschke C.I., Clinical Findings of Participants with Severe Bronchiectasis on Baseline Low-dose CT Screening for Lung Cancer). 22 Using different scales, 11% and 23% of the participants from Pamplona and New York, respectively, had bronchiectasis on their LDCT. In the Spanish study, individuals with bronchiectasis more frequently had lung nodules and a greater proportion was not cancer.…”

“…In the Spanish study, individuals with bronchiectasis more frequently had lung nodules and a greater proportion was not cancer. 22 These differential diagnoses led to an increased level of follow-up imaging studies or even invasive diagnostic procedures. Therefore, often, in clinical practice-when infection is a possible differential diagnosis-antibiotic treatment and a follow-up CT are recommended.…”

Airway inflammation in patients with bronchiectasis

“…Tri familije adhezionih molekula učestvuje u ovom procesu: selektini, integrini CD 11/CD 18, i super familija imunoglobulina uključujući intracelularni adhezioni molekul (ICAM) 1 i vaskularni adhezioni molekul (VCAM)1 i CD 47. Adherirani neutrofili migriraju u disajne puteve pod dejstvom hemotaktičnih faktora (IL 8, LT B4) [17,18]. Aktivirani neutrofili luče brojne proteaze, uključujući neutrofilnu elastazu, katepsin G i proteinazu 3.…”